25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM studyGrant A. McArthur, A. Ribas, Isabelle Rooney et al.|European Journal of Cancer|2015Cited by 10
Phase 3, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib + Cobimetinib in Previously Untreated Brafv600 Mutation–Positive Patients with Unresectable Locally Advanced or Metastatic Melanoma (Nct01689519)Grant A. McArthur, Brigitte Dréno, Luis de la Cruz‐Merino et al.|Annals of Oncology|2014Cited by 3